ProPhase Labs, Inc.

ProPhase Labs, Inc. is a U.S.-based life sciences and consumer health company with operations spanning diagnostic services, personal genomics, and branded dietary supplements. Through subsidiaries including ProPhase Diagnostics and Nebula Genomics, it combines laboratory testing, DNA sequencing, and consumer wellness products under one corporate structure.

−304,1 %

31,9 %

−339,3 %

0.06

0.06

— ProPhase Labs, Inc.
%
Personal genomics35% Consumer DNA sequencing and genetic testing services offered through Nebula Genomics and DNA Complete.
Diagnostic services25% Laboratory testing services, including COVID-19 and other molecular diagnostics.
Consumer products30% Branded OTC health and dietary supplement products sold under the TK Supplements line.
Licensing and development10% Development and commercialization of novel drugs, compounds, diagnostics, and related IP.

The company sells primarily to consumers seeking genetic insights, health information, and wellness products, with...

  • Personal genomics consumersprimary

    Buy DNA sequencing and genetic testing for ancestry, health risk, and trait insights.

  • Diagnostic testing customersprimary

    Buy laboratory testing services, historically including COVID-19 and molecular diagnostics.

  • Supplement consumerssecondary

    Buy TK Supplements products for energy, sexual vitality, and general wellness.

  • Licensing and development counterpartiesemerging

    Partners or license holders involved in drug, compound, and diagnostic commercialization.

ProPhase Labs is headquartered in the United States and its operating footprint is centered there, including laboratory...

  • •Headquartered in the United States
  • •Laboratory operations have been based in New Jersey
  • •Consumer genomics and supplements are primarily U.S.-focused
  • •Licensing and product development are managed from the U.S.
  • •No country-level revenue disclosure was provided in the excerpts

The company is focused on building and commercializing multiple health-related businesses, including genomics,...

01
Grow personal genomics and consumer health offeringsmedium-term

These businesses provide recurring consumer-facing revenue opportunities and brand-building potential.

02
Commercialize licensed and developed assetsmedium-term

Drug, compound, and diagnostic development can create higher-value future revenue streams if successful.

03
Maintain access to capitalshort-term

The business mix includes development-stage activities that require funding before they can scale.

The company faces execution risk across several businesses, including consumer complaints, sequencing delays,...

critical

Insurance reimbursement and collections risk

Diagnostic revenue depends on payor reimbursement and timely claim collection.

Scope
ProPhase Diagnostics
Materiality
high
high

Consumer complaints and reputational damage

DNA testing customers rely on trust, timely results, and data handling quality.

Scope
Nebula Genomics and DNA Complete
Materiality
high
high

Sequencing and fulfillment delays

A change in sequencing lab can delay results and increase service backlogs.

Scope
Personal genomics operations
Materiality
high
high

Financing and liquidity dependence

Development and commercialization activities require external capital before scale.

Scope
Equity, debt, and ATM financing
Materiality
high
medium

Litigation and privacy exposure

Genetic data handling can trigger privacy claims and regulatory scrutiny.

Scope
Nebula Genomics and customer data
Materiality
medium
medium

Digital asset volatility

Any crypto treasury activity can create mark-to-market and custody risk.

Scope
Potential digital asset holdings
Materiality
medium
Revenue recognition by business line
Affects quarterly comparability and reported growth across segments
Accounts receivable and claim recoverability
Can materially affect cash flow and bad debt expense
Contingent liabilities and legal reserves
Can affect expenses, liabilities, and uncertainty disclosures
Stock-based compensation
Impacts operating expenses and dilution analysis
Asset impairment and valuation
Can create non-cash charges if expected cash flows weaken

VERACYTE, INC.

VCYT · Services-Medical Laboratories

Profound Medical Corp.

PROF · Surgical & Medical Instruments & Apparatus

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Tempus AI, Inc.

TEM · Services-Computer Programming, Data Processing, Etc.

Co-Diagnostics, Inc.

CODX · Surgical & Medical Instruments & Apparatus

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

: 29/04/2026